Member Info for douve87

Really hope this offer never materialises or falls through. I don't think the offer is enough and the 'increased offer' (which at present is actually a decreased monetary offer, never seen a revised offer come in under before) an insult. Already mentioned the issues with CYBG below, I feel there are better suitors out there or VM better off on own.

Not saying I believe them, but what's a code 10 buy meant to mean?

Personally don't think it's enough. I'm against the takeover as don't think they're the best partner for VM and the amount is not enough. As a result I think it's best we stay as we are or wait for another partner.

I agree until a deal is signed, sealed and delivered it's not a deal so they won't say anything but equally they shouldn't speculate/mislead with ambiguous 'monitizing assets' like statements. I've already mentioned that we are partly to blame by reading too much into things buts it's hard not to with such statements.

I agree and i hope you're right. Like I said in a previous post never questioned the BoD's integrity (which is no mean feat in in this sector or on aim) or question their abilities as scientists but still yet to be convinced by their commercial abilities and rather obviously won't be til we do our first deal. Happy to hold and convinced we will come good but feel the majority of us who use this board (myself included) try too hard to look for positive signs and kid ourselves that something is imminent when it's not and 'monitizing our assets in the near to short term' type statements by CH don't help us or the BOD. As mentioned I already feel aggrieved by CH due to this statement closely followed by an oo which isn't really fair to CH considering how little time he's been with scancell but is the way I feel.

Bl**dy autocorrect. Should be 'in to that as confidence' not until. And 'monitizing of assets' not monitoring.

Unless it was the way that particular statement was said at the presentation i wouldn't read too much until that as confidence. To me it just seems an acceptance of the position we're in, no deals so far so will try again after clinical data. I'm little disappointed by initial overview as I get the impression monitoring of assets does not seem imminent on any platform and seems to be backed up by the recent oo so already feel a little aggrieved by CH's misleading statements (so not a great start). Trying not be too harsh and hope I'm wrong but get impression next significant news will be Nov and even that won't be a commercial deal. Biggest quality required for a scancell investor is patience but convinced it will eventually come good.

Personally though i feel there are more suitable suitors that I would favour over CYBG; so I'm hoping they pull out.

I agree CYBG def need VM. more than VM. need CYBG. I was concerned over the weekend when I read this article. http://www.thisismoney.co.uk/money/news/article-5723379/Police-probe-CYBG-just-launches-bid-Virgin-Money.html With the losses, misselling compensation and police probe, CYBG are not very attractive partners and less so at their offer price. It will either have to be significantly higher or failing that as many others have said I'm happy to continue as we are (although it would be nice if our share price remained in this region as we were criminally undervalued before).

You make a good point but my question would then be what do Biontech bring to the party. Surely a deal direct with the likes of Genentech should be the aim not Biontech, as Genentech have the sufficient funds and capabilities to take our science forward.

Crumbs I understand that and stated that it would be a catalyst but it would still make me question the bod's commercial capabilities as other biotechs have managed similar deals at lesser stages on lesser science without the dilution that we've all endured here.

Hi konar think it may have been me that you're referring to as I stated that I did not believe Biontech had sufficient funds to do a deal for either platform. Don't get me wrong a commercial deal would act as a catalyst to hopefully greater things and whatever way you look at it would be a positive. But I don't hold the same enthusiasm for doing a deal with Biontech that others seemingly do. Considering the deals that are currently happening in the biotech market for seemingly lesser science, with much greater upfront payments then Biontech can afford and considering we've all justified the various rounds of funding and dilution by saying that the more testing we do ourselves the greater the value we will justify. If we do a deal with Biontech for an upfront payment of 10million I will question the bod and their commercial capabilities. I believe our bod are honest and great scientists (not questioning their integrity) but like I said when the most recent oo was announced I am starting to question their commercial abilities and a 10million deal with Biontech would not allay those concerns (quite the opposite). So hoping for a commercial deal in "the near to short term"but have higher ambitions then some of the figures stated on here. Btw great news about the patent don't believe it's been factored into share price at these prices but unfortunately not convinced that it will have a dramatic impact as the market doesn't seem to be able to value our science or ip.

May be a dim question but are everyone else's oo shares now appearing in their accounts?

Well that's me all funded for the oo with a few extra subscribed for to put me on a round 119k. Admittedly I sold some on Mon but get some free shares for the trouble, and like Chelsea get the satisfaction of knowing this money is directly benefitting scancell and cancer reasearch (so its a win win for me).

Think it may have been mentioned in the past but does anyone think the left field news could be scancell and biontech going into a full partnership together and then listing on the stock market. Don't know the practicalities of such a move and what kind of deal we would get or even if this would be the most lucrative way for investors but it would be a good move in Biontech's aim to be the European Genentech and would be left field. Any thoughts?

Are the trades showing on lse misleading again as there seems to be about 4 times as many sales than buys and yet we're up? What am I missing?

Good point and that would be great (compared to no deal/partnership) but if it was a deal similar to what we've done with isa I don't think it would have a major impact on shareprice as there would still be risk that the payments never come to fruition and assuming they did (as I have no concerns at present regarding the science) the real spoils wouldn't come for years later. After all this wait the bod really need to deliver a large cash upfront deal. This would give the market an indication of the value of our science, increase our shareprice and show that the bod know what they're doing. Considering the types of deals happening at present in this sector I don't think it's unreasonable

Also just thought going back to our previous conversation where you implied I was undervaluing our science but you've just mentioned you think a commercial deal may develop out of Biontech partnership (which I hope it does) but they don't have billions they've only just raised 270million themselves and that wouldn't all come to us. So not the size of deal I feel scancell science deserves.

I agree very impressive partnerships with regards the science just not the finance. Does anyone know whether our new shares in issue total of 374,469,098 includes what the bod would be awarded if we were to meet their share price targets. I'm presuming not but was wondering if anyone knew what the total shares in issue would be if all shares were awarded. I also assume this doesn't inc the new shares planned for the p.o.? The reason I ask is I did a quick calculation and if we were to get a billion each share would be worth 50p less since dilution (previously about £3.20 now about £2.70). Just a bit of fun but curious?

Yes but both are costing us money, neither partnership to date is actually providing funding. Although impressive neither are the partnership deals investors were hoping for.